Rainer Blasczyk is Full Professor of Transfusion Medicine and Head of the Institute of Transfusion Medicine and Transplant Engineering at Hannover Medical School (MHH), Hanover, Germany since 1998 as well as board member of the Transplantation Center at Hannover Medical School since 2019. He graduated in medicine from the Universities Bochum and Essen before completing postgraduate training at the Universities of Marburg, Essen, Duesseldorf and Berlin, where he started to work on Molecular Immunogenetics in 1993. After being appointed to his current position he initiated the research on transplant engineering.

Professor Blasczyk has a long term research interest in solid organ transplantation and transplantation immunology with a main focus on transplant tolerance and transplant engineering. His work centers around the alloimmune response in organ transplantation and therapeutic interventions to combat rejection and infection. This includes cellular and humoral immunotherapy as well as genetic and transplant engineering approaches to achieve transplantation tolerance.

Professor Blasczyk is founder and chairman of the Immunotherapy Foundation. He has been a member of the Advisory Board on Blood Products of the German Ministry of Health, President of the German Society of Immunogenetics (DGI) and the German Society of Transfusion Medicine and Immunohematology (DGTI) as well as a Board Member of the European Society of Immunogenetics (EFI). 

His research aims to prevent transplant rejection by genetic allograft engineering. Professor Blasczyk is considered a pioneer in transplant engineering and highly specialized in the field of histocompatibility and immunogenetics. He is particularly interested in the genetic structure, molecular function and regulation of histocompatibility systems in order to identify therapeutic targets for graft engineering to substantially improve clinical outcome of transplantation. Professor Blasczyk has initiated the Research Network on Invisible Organs, a pioneering project on transplant engineering to combat organ rejection.